Get the Stockscreener App
1.145
0.00%
0.005
Oncolytics Biotech Inc stock is traded at $1.145, with a volume of 57,318.
It is up +0.00% in the last 24 hours and up +3.64% over the past month.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatment. The other projects in the company's pipeline include, Bracelet-1 for treatment of Breast Cancer, Goblet cohort-1, Goblet cohort-5 for treatment of Gastro-Intestinal Cancer among others.
See More
Previous Close:
$1.14
Open:
$1.14
24h Volume:
57,318
Relative Volume:
0.14
Market Cap:
$87.62M
Revenue:
-
Net Income/Loss:
$-20.59M
P/E Ratio:
-3.42
EPS:
-0.3348
Net Cash Flow:
$-17.99M
1W Performance:
-4.20%
1M Performance:
+3.64%
6M Performance:
-2.56%
1Y Performance:
-33.72%
1-Day Range:
$1.13
$1.17
1-Week Range:
$1.12
$1.20
52-Week Range:
$0.8401
$1.75
Oncolytics Biotech Inc Stock (ONCY) Company Profile
Oncolytics Biotech Inc Stock (ONCY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-06-22 | Initiated | Maxim Group | Buy |
| Feb-17-21 | Initiated | H.C. Wainwright | Buy |
Oncolytics Biotech Inc Stock (ONCY) Latest News
Oncolytics Biotech (TSE:ONC) Shares Pass Above 200-Day Moving AverageShould You Sell? - MarketBeat
Oncolytics Biotech® Announces Fireside Chat at the Cantor Global Healthcare Conference - GuruFocus.com
Oncolytics Biotech Inc. (NASDAQ:ONCY) Sees Significant Increase in Short Interest - MarketBeat
Oncolytics Biotech (TSE:ONC) Shares Cross Above 200-Day Moving AverageShould You Sell? - MarketBeat
Oncolytics Biotech Inc - Stockhouse Publishing
What is Oncolytics Biotech, Inc. (ONCY) Stock Return on Shareholders’ Capital? - SETE News
Oncolytics Biotech (TSE:ONC) Stock Price Crosses Above 200-Day Moving AverageWhat's Next? - MarketBeat
Biotech Advances Gain Momentum Amid October’s Rising Breast Cancer Rates and Awareness Efforts - Baystreet.ca
Ratio Analysis: Unpacking Oncolytics Biotech, Inc. (ONCY)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
What was Oncolytics Biotech, Inc. (ONCY)’s performance in the last session? - US Post News
Oncolytic Virus Therapy Market Set to Witness Significant Growth by 2024-2031:Oncolytics Biotech Inc, Circio - EIN News
Stocks In Play: Oncolytics Biotech® Inc. - Barchart
Oncolytics Biotech (NASDAQ:ONCY) Stock Price Down 5.3%Here's Why - MarketBeat
ONCY Stock Up on Regulatory Update From Breast Cancer Program - MSN
A new trading data show Oncolytics Biotech, Inc. (ONCY) is showing positive returns. - SETE News
Quarterly Snapshot: Quick and Current Ratios for Oncolytics Biotech, Inc. (ONCY) - The Dwinnex
Oncolytics Biotech (TSE:ONC) Shares Down 7.9%Here's Why - MarketBeat
Examining Oncolytics Biotech, Inc. (ONCY) more closely is necessary - US Post News
Oncolytics seeking FDA meeting to discuss registration-enabling study - MSN
ONCY’s 52-Week Rollercoaster: From $0.84 to $2.10 – What’s Next for Investors? - The InvestChronicle
Global cancer cases surge while biotech firms accelerate treatment innovations - Benefits and Pensions Monitor
Oncolytics targets accelerated approval for oncolytic virus therapy - Yahoo Finance
Oncolytics Biotech® Announces Key Progress and Upcoming Studies for Breast and Pancreatic Cancer Treatments, Prepares for FDA Accelerated Approval Path - The Malaysian Reserve
Oncolytics Biotech (TSE:ONC) Stock Price Up 11.8%Should You Buy? - MarketBeat
Stocks In Play: Oncolytics Biotech® Inc. By Baystreet.ca - Investing.com Canada
Stocks In Play: Oncolytics Biotech Inc By Baystreet.ca - Investing.com Canada
Oncolytics Biotech® Inc. - Baystreet.ca
Oncolytics Biotech’s Cancer Drug Aims for Fast-Track Approval - TipRanks
FDA Oncology Approvals Accelerate as Global Cancer Rates Set to Climb 77% - Baystreet.ca
Active Biotech Alert: FDA Approves 16 New Cancer Treatments as Global Cancer Rates Skyrocket - Financial Content
FDA Approves 16 New Cancer Treatments As Global Cancer Rates Skyrocket - Barchart
Stocks In Play: Oncolytics Biotech Inc - Barchart
Oncolytics Biotech (TSE:ONC) Hits New 52-Week Low at $1.16 - Defense World
Oncolytics Biotech's SWOT analysis: pela drug potential drives stock outlook By Investing.com - Investing.com Australia
Oncolytics Biotech's SWOT analysis: pelareorep progress lifts stock outlook - Investing.com India
Oncolytics Biotech (TSE:ONC) Reaches New 12-Month Low at $1.20 - Defense World
Promising Progress in Oncology as Cancer Deaths Decline and Research Grows - Baystreet.ca
Optimism Grows in the Fight Against Cancer as Breakthroughs and Funding Increase - Benzinga
Global study predicts sharp rise in cancer rates among men by 2050 - Benefits and Pensions Monitor
How Critical Demand for Metastatic Breast Cancer Therapies is Producing a Multi-Billion Dollar Opportunity for Biotechs - ForexTV.com
Investors Watch Key Players in Oncology as Cancer Cases Set to Skyrocket - Baystreet.ca
Oncolytics Biotech (TSE:ONC) Given New C$3.50 Price Target at Raymond James - Defense World
Oncolytics Biotech (NASDAQ:ONCY) Receives Buy Rating from HC Wainwright - Defense World
Oncolytics Biotech (TSE:ONC) Price Target Raised to C$3.50 at Raymond James - MarketBeat
Global Cancer Rates Surge as Biotech Innovators Work on New Therapies - cnhinews.com
Abbvie Inc (ABBV-N) QuotePress Release - The Globe and Mail
Recent Breakthroughs in Cancer Research Could Impact These Key Companies - Baystreet.ca
Oncolytics Biotech (NASDAQ:ONCY) Earns Buy Rating from HC Wainwright - MarketBeat
Oncolytics Biotech reports positive results from breast cancer study | 2024-09-19 | Investing News - Stockhouse Publishing
Oncolytics Biotech reports promising breast cancer study results - Investing.com India
Oncolytics Biotech reports promising breast cancer study results By Investing.com - Investing.com Australia
Oncolytics Biotech Inc Stock (ONCY) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.75%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):